Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Heartbeam Inc (BEAT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BEAT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.5
1 Year Target Price $4.5
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.55% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 43.58M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 2 | Beta -0.72 | 52 Weeks Range 0.91 - 3.48 | Updated Date 08/29/2025 |
52 Weeks Range 0.91 - 3.48 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.16 | Actual -0.15 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -159.49% | Return on Equity (TTM) -315.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 38522718 | Price to Sales(TTM) - |
Enterprise Value 38522718 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.99 | Shares Outstanding 34311600 | Shares Floating 24806593 |
Shares Outstanding 34311600 | Shares Floating 24806593 | ||
Percent Insiders 23.79 | Percent Institutions 10.48 |
Upturn AI SWOT
Heartbeam Inc
Company Overview
History and Background
Heartbeam, Inc., formerly known as Electro-Sensors, Inc., was founded in 1968. It has evolved from a sensor technology company into a cardiac monitoring solutions provider. Key milestones include the development and FDA clearance of its AIMIGo technology.
Core Business Areas
- AIMIGo (Acute Infarction Monitoring at home Go): This is Heartbeam's flagship technology, focusing on detecting acute myocardial infarction (AMI), commonly known as a heart attack, at home using a credit-card sized personal ECG device.
- Telehealth Solutions: Heartbeam aims to integrate its technology with telehealth platforms to enable remote cardiac monitoring and facilitate timely medical intervention.
Leadership and Structure
Branislav Vajdic is the Chief Executive Officer. The company has a board of directors and is structured with departments for research and development, operations, and commercialization.
Top Products and Market Share
Key Offerings
- AIMIGo: The AIMIGo system is designed for at-home detection of heart attacks. Market share is currently minimal as the product is in the pre-commercial stage. Competitors include traditional ECG monitoring systems and other wearable cardiac monitoring devices from companies like AliveCor and Medtronic.
Market Dynamics
Industry Overview
The cardiac monitoring market is growing due to an aging population, increasing prevalence of cardiovascular diseases, and advancements in wearable technology.
Positioning
Heartbeam aims to disrupt the traditional cardiac monitoring market by providing a convenient and cost-effective at-home solution for early heart attack detection. Its competitive advantage lies in its novel 3D vector ECG technology.
Total Addressable Market (TAM)
The global cardiac monitoring market is estimated to be in the billions of dollars. Heartbeam is positioned to capture a segment of this market by focusing on at-home AMI detection.
Upturn SWOT Analysis
Strengths
- Novel 3D vector ECG technology
- Potential for early heart attack detection at home
- Focus on a large and growing market
- Experienced leadership team
Weaknesses
- Pre-commercial stage with limited market presence
- Reliance on regulatory approvals
- Limited financial resources
- Competition from established players
Opportunities
- Partnerships with telehealth providers
- Expansion into new markets
- Development of new cardiac monitoring applications
- Increasing adoption of wearable technology
Threats
- Regulatory hurdles
- Competition from established players
- Technological obsolescence
- Economic downturn
Competitors and Market Share
Key Competitors
- ALIV
- MDT
- BSX
Competitive Landscape
Heartbeam faces intense competition from established medical device companies with greater financial resources and broader product portfolios. Its success depends on differentiating itself through its unique 3D vector ECG technology and focusing on the at-home AMI detection market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal due to the pre-commercial stage.
Future Projections: Future growth projections are dependent on regulatory approvals and successful commercialization of AIMIGo. Analyst estimates vary widely, reflecting the high uncertainty.
Recent Initiatives: Recent initiatives include clinical trials, regulatory submissions, and strategic partnerships.
Summary
Heartbeam is a high-risk, high-reward company in the pre-commercial stage. Its AIMIGo technology offers the potential to disrupt the cardiac monitoring market, but the company faces significant challenges, including regulatory hurdles, competition, and limited financial resources. Successful commercialization of AIMIGo is critical for its future growth. Investors should carefully consider the risks and uncertainties before investing in Heartbeam.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC), Investor Presentations, Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heartbeam Inc
Exchange NASDAQ | Headquaters Santa Clara, CA, United States | ||
IPO Launch date 2021-11-11 | CEO, Chief Business Officer & Director Mr. Robert P. Eno | ||
Sector Healthcare | Industry Health Information Services | Full time employees 19 | Website https://www.heartbeam.com |
Full time employees 19 | Website https://www.heartbeam.com | ||
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing ambulatory electrocardiogram solutions that enable the detection and monitoring of cardiac disease inside and outside a healthcare facility setting. The company develops three-dimensional vector images of cardiac electrical activity. It is developing HeartBeam AIMIGo, a credit card-sized cloud-based diagnostic software systems to address heart attack detection. The company was incorporated in 2015 and is based in Santa Clara, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.